Colgate-Palmolive

CL · NYSE

$94.54+$1.68 (+1.81%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $92.86

CL analyst rating

BuyConsensus of 17 analysts over the last 12 months. 65% rate it a buy.

Strong buy0
Buy11
Hold6
Underperform0
Sell0

12-month price target · 25 analysts

Average $99.23 (+5.0% upside)

Low: $75.75
Now: $94.54
High: $115.50

Upgrades and downgrades

The latest rating actions, newest first

CL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 19, 2026	Maintains	Overweight	$103.00 → $104.00	58%
Wells Fargo	Oct 5, 2026	Maintains	Equal-Weight	$95.00 → $90.00	57%
Piper Sandler	Sep 21, 2026	Maintains	Overweight	$98.00 → $95.00	51%
RBC Capital	Sep 8, 2026	Maintains	Outperform	$104.00	45%
UBS	Aug 3, 2026	Maintains	Buy	$106.00 → $109.00	62%
TD Cowen	Aug 3, 2026	Maintains	Hold	$85.00 → $90.00	58%
JP Morgan	Aug 3, 2026	Maintains	Overweight	$104.00 → $103.00	58%
RBC Capital	Aug 3, 2026	Maintains	Outperform	$102.00 → $104.00	45%
Evercore ISI Group	Aug 3, 2026	Maintains	Outperform	$100.00 → $101.00	59%
Barclays	Jul 21, 2026	Maintains	Equal-Weight	$80.00 → $87.00	62%

The case for and against

Updated Oct 14, 2026

Bull case

Colgate-Palmolive is attractive because its international business has delivered mid- to high-single-digit organic growth, with Europe adding about 300 bps of toothpaste share since 2016 through a proven two-brand strategy, while Hill’s contributes nearly one-fourth of sales and continues to expand in premium, vet-driven pet nutrition. The outlook is further supported by margin expansion potential and cost discipline, including the expanded Global Growth and Efficiency Program, which targets $500–575MM of annual savings with a three- to four-year cash payback and an after-tax return above 30%. Although North America has been a drag with negative organic sales in most of the past two years, the business can stabilize as innovation and a sharper therapeutic positioning narrow share losses and reaccelerate growth.

Bear case

Colgate-Palmolive is facing a negative outlook because its recent underperformance appears largely self-inflicted, with excessive pricing, reduced promotions, under-investment in North America marketing, and product decisions that ceded share to P&G, Haleon, and Dawn. North America has been down about 2% over the last 8 quarters and lagged HPC peers by roughly 250 bps, while its toothpaste portfolio remains more than a 50% discount to Haleon’s and 28% below P&G’s, limiting premium mix and pricing power. Added pressure from about $300M of incremental 2026 raw material and logistics costs, currency exposure across emerging markets, and slower new-product execution suggests gross margin and organic growth recovery may remain constrained.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.